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Abstract
Background: Despite the rapid adoption of the World Health Organization’s 2013 guidelines, children continue to
be infected with HIV perinatally because of sub-optimal adherence to the continuum of HIV care in maternal and
child health (MCH) clinics. To achieve the UNAIDS goal of eliminating mother-to-child HIV transmission, multiple,
adaptive interventions need to be implemented to improve adherence to the HIV continuum.
Methods: The aim of this open label, parallel, group randomized trial is to evaluate the effectiveness of Continuous
Quality Improvement (CQI) interventions implemented at facility and health district levels to improve retention in
care and virological suppression through 24 months postpartum among pregnant and breastfeeding women
receiving ART in MCH clinics in Kinshasa, Democratic Republic of Congo. Prior to randomization, the current
monitoring and evaluation system will be strengthened to enable collection of high quality individual patient-level
data necessary for timely indicators production and program outcomes monitoring to inform CQI interventions.
Following randomization, in health districts randomized to CQI, quality improvement (QI) teams will be established
at the district level and at MCH clinics level. For 18 months, QI teams will be brought together quarterly to identify
key bottlenecks in the care delivery system using data from the monitoring system, develop an action plan to
address those bottlenecks, and implement the action plan at the level of their district or clinics.
Discussion: If proven to be effective, CQI as designed here, could be scaled up rapidly in resource-scarce settings
to accelerate progress towards the goal of an AIDS free generation.
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Background
In 2013, the World Health Organization (WHO) recom-
mended lifelong triple antiretroviral therapy (ART) to all
HIV-positive pregnant and breastfeeding women regard-
less of CD4 count (Option B+) [1]. By 2015, 91% of the
1.1 million women receiving antiretroviral medicines for
prevention of mother-to-child transmission of HIV
(PMTCT) were on lifelong ART. [2] However, because of
high rate of loss-to-follow up (LTFU) and poor quality of
care across the continuum of HIV care in Maternal and
Child Health (MCH) clinics [3–5], over 150,000 children
were newly infected [6]. Without substantial improvement
in the quality of HIV care in MCH clinics, particularly in
the resource-poor settings, the global goal of an AIDS free
generation might not be achieved even if all pregnant
women were tested and initiated on ART. [7]
Numerous interventions have been proposed to address
the low performance of HIV care delivery system in MCH
clinics. However, virtually all of those interventions focus
on a single component of the healthcare system perform-
ance: the patient [8]. Organizational factors such as avail-
ability of an effective supply chain management, regular
supervision and support, schedule of services, use of
standard operational procedures, staff-patient ratio, model
of care; provider factors (e.g. training, satisfaction and sup-
port) and patient-level factors (e.g., sociodemographic,
perceived and measured health, HIV knowledge, distance
to the clinics, and availability of psychosocial support) and
their interrelationship are key determinants of healthcare
delivery system performance [8]. A package of interven-
tions aimed at each component of the service triad
(healthcare delivery systems, providers, and beneficiaries),
that can be easily scaled-up in resource-poor settings, is
needed to produce the rapid gain in service delivery per-
formance that is required for the elimination of the
mother-to-child transmission of HIV.
Quality Improvement (QI) Collaborative is one of the
most popular methods for organizing sustained improve-
ment efforts at hospitals and ambulatory practices
worldwide. In the Breakthrough Series approach, this is
also referred to as continuous quality improvement
(CQI) [9], where QI teams from multiple sites across a
region or country are brought together to focus on a
common problem. However, despite its popularity, CQI
effectiveness has never been demonstrated in a random-
ized trial or a well-designed comparative study [10]. In a
large non-randomized comparative study evaluating the
effectiveness of CQI interventions in improving the
quality of care for HIV-infected patients, in clinics re-
ceiving funding from the Ryan White Comprehensive
AIDS Resources Emergency Act in the United States of
America [11], the intervention did not significantly in-
crease the proportion of patients with a suppressed viral
load. However, since 2011, South Africa has experienced
a remarkable improvement across all key indicators in
the PMTCT cascade [12], attributed, at least in part, to
the QI initiatives implemented at facility level [12–16].
But whether the results can be reproduced in poorer
settings in sub-Saharan Africa, where the existing health
infrastructure including capacity for strong monitoring
and evaluation are often weak, remain to be shown.
The aim of our study is to evaluate the effectiveness of
CQI interventions, implemented at facility level using
participatory data-driven approaches, on-site monitor-
ing, and supervisory support, on long term retention in
care and sustained virological suppression among preg-
nant and breastfeeding women who start lifelong ART
in MCH clinics. A pragmatic, open label, parallel, group
randomized design will be used. In this paper, we want
to describe the methods we plan to use to this effect.
Methods
Study setting
The proposed study will be implemented in Kinshasa,
the capital city province of the Democratic Republic of
Congo (DRC). DRC is one of the 21 sub-Saharan Africa’s
with the largest unmet need for PMTCT [7]. DRC’s
National AIDS Strategic Plan goal calls for the virtual
elimination of MTCT (MTCT rate <5%) by 2017.
Starting in October 2013 and with support from the
United States President's Emergency Plan for AIDS
Relief (PEPFAR) and the Global Fund to Fight AIDS,
Tuberculosis and Malaria, DRC has been progressively
scaling-up Option B+ (ART for life to all HIV+ pregnant
women). Roughly 9 in 10 pregnant women in DRC
attend at least one antenatal care (ANC) visit before
delivery, surpassing 97% in Kinshasa [17, 18]. For over a
decade, through a strong collaboration between the
Kinshasa School of Public Health (KSPH), the Ministry of
Health, the main faith-based organizations that run most
of the primary healthcare clinics in Kinshasa [i.e. the
Salvation army (Armée du Salut) and the Catholic Health
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Board (Bureau Diocésain des Oeuvres Médicales
(BDOM)], our team has provided technical support for
MCH clinics in Kinshasa and elsewhere in DRC for the
implementation of HIV prevention, care and treatment
programs including PMTCT [18–32]. In 2010, as part
of this technical support, our team developed and sup-
ported the implementation of a mother-infant register
to help monitor PMTCT care provided in MCH clinics
via collection of key program indicators. The registry
was modeled after the WHO’s Three Interlinked Patient
Monitoring Systems for HIV Care/ART, MCH/PMTCT
(including malaria prevention during pregnancy), and
TB/HIV: Standardized Minimum Data Set and Illustra-
tive Tools and has been adapted by the National AIDS
Program for the monitoring of Option B+ across the
country.
Randomization
Although the interventions will be implemented
mainly at the clinic level, because the first level of
supervision for MCH clinics is the Health District
Bureau, and to avoid potential contamination of the
control clinics, the unit of randomization with be the
health district. All 35 health districts in Kinshasa will
be eligible. Health districts will be stratified by urban
and peri-urban location and randomized to CQI or
standard of care using a computer random generated
number and the list of district in each stratum ordered
alphabetically.
Eligibility criteria
In each district, the top three MCH clinics in terms of
number of HIV-infected pregnant women served in 2015
and 2016 will be selected. All HIV-infected pregnant and
breastfeeding women receiving care at any participating
clinics during the study period and their HIV-exposed
infants will be eligible for enrollment. Participants will be
excluded if they refuse to participate in the study. A writ-
ten consent will be obtained from each participating
woman as well as a written permission for the participa-
tion of their HIV exposed infant (HEI).
Study implementation
The study will be implemented in two phases. In Phase
I, to inform the design of CQI interventions, we will
collect information on the key characteristics of the
healthcare delivery system in the facilities eligible for the
study. We will also strengthen the current monitoring
and evaluation system in MCH clinics to insure that
both programmatic and clinical outcome indicators that
will be needed for the CQI implementations will be
timely available before randomization occurred.
Interventions
The package consists of CQI interventions implemented
at facility level using participatory data-driven approaches,
on-site monitoring, and supervisory support. In health
districts randomized to intervention, we will set up a qual-
ity improvement team at the level of the district that in-
cludes the supervisor from the health district Bureau and
the head of PMTCT from each of the participating MCH
clinics, and at the level of each clinic. A clinic level QI
team will include at least one staff each from ANC, deliv-
ery/maternity, and well-child services. A study staff mem-
ber will serve as rapporteur of each QI team. Immediately
following randomization, we will bring together QI teams
in a half a day meeting during which they will review
monitoring data on program and clinical outcome indica-
tors and identify key bottlenecks in the care delivery sys-
tem that is affecting those outcomes. The group will then
develop and agree on an action plan to modify the priority
bottlenecks as well as the key indicators to include in the
quarterly data for actions reports that will be used to
monitor the changes resulting from the implementation
of the action plan. QI teams will be responsible for the
implementation of the action plan at the level of their re-
spective clinics. A member of the health district QI team
and a study team member will visit each participating
clinic at least once a month to supervise and support
the implementation of the action plan. Every 3 months,
using data from the monitoring system, the study team
will generate a quarterly report including a color-coded
dashboard for tracking changes using the ‘traffic light’
approach. An indicator will score green when the target
has been achieved, yellow/amber when there is a pro-
gress from the baseline value without reaching the tar-
get, and red when there is no progress or downward
movement. The report will be generated for each par-
ticipating clinic in the intervention group and shared
with the QI teams and the management of the clinic.
QI teams will be brought together to review these indi-
cators, share experience, identify remaining gaps in the
service delivery, and develop a new priority action plan
for the next quarter in cycle for 18 months. To limit
possible contamination, all staff from a randomized
district/clinic who may have a dual appointment in
another facility will be excluded from QI teams.
Standard of care
In health districts randomized to standard of care, the
same strengthening of the data collection system for the
monitoring of indicators as in the intervention group will
be implemented. At least once a month, a study staff will
visit each clinic irrespective of their randomization to ex-
tract information for the mother-infant register into an
electronic database. No report on indicators will be pro-
duced for these clinics for the duration of the study. Staff
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from clinics and health district bureau in the standard of
care group will not be associated with the quarterly review
of the indicators. The study will not interfere with any
other HIV service provision activity in the standard of care
group.
Masking
By the nature of the intervention, it will not be possible to
mask the intervention to clinics and study staffs. However,
participants (HIV-infected mothers) will not be informed
about the randomization nor the intervention.
Outcomes
Two primary outcomes will be considered: loss-to-
follow-up (the proportion of participants for whom
the whereabouts is unknown at the evaluation time)
and virological suppression (proportion of participants
with undetectable viral load). Several secondary out-
comes will also be considered including timely infant
HIV diagnosis, retention in care, non-adherence to
scheduled visits, virological suppression, MTCT rates,
and survival (see Table 1 for definitions). Indicators
used for the dashboard will also be analyzed as sec-
ondary outcomes.
Sample size justification
Our sample size estimation is based on primary out-
come LTFU. The minimum sample size to detect the
expected difference of proportions assuming individual
randomization with a level of significance set at 95%
(2-sided) and at 80% power was first calculated and
adjustment was made by inflating the individually ran-
domized sample size by a factor given by d ¼ 1þ ρ m−1ð Þ
; where m is the average cluster size (10) and ρ the in-
ternal variability that represents how strongly individuals
within clusters are related to each other (intracluster cor-
relation (ICC)) [33]. Inflating the individually randomized
sample size by this factor counteracts the loss of power
due to a clustered design [34]. Analysis of data from a pre-
vious trial in some of those clinics showed ICC for various
outcomes ranging from 0.20 to 0.30 [35]. Using data from
our trial on conditional cash transfer which showed a
20.3% LTFU at 6 weeks postpartum in the control group
[36], assuming that by 24 months postpartum, at least
30% of participants would have experienced the outcome
in the control group and that the CQI interventions will
be considered effective if there is an absolute reduction in
LTFU by 30% at 24 months (namely a proportion of LTFU
of 21%) in the intervention group, we determined that 367
mother-infant pairs will be needed in each arm under in-
dividual randomization. Adjusting for the inflation factor,
under a conservative ICC of 0.30, we will need to enroll
1358 participants per arm or 2716 HIV-infected women.
Data collection
Data for primary and secondary outcome will be col-
lected via the mother-infant register. The following key
information is documented in the register: a maternity
code that is used to link mother and infant, address and
telephone number, gestational age, date of birth, date of
reference to HIV care and treatment if any and location
of the referral, and other information necessary to calcu-
late PEPFAR’s PMTCT indicators including information
on infant feeding practices, cotrimoxazole prophylaxis at
subsequent visits, date of first sample collection for early
infant diagnosis at 6 weeks and the result, a second sam-
ple collection and result at 9 months, and eventually a
serological test at 18 months for all infants with HIV-
negative PCR results is also documented. At least once a
month, a study nurse equipped with a laptop will visit
each participating clinic to extract information from the
register into an electronic database.
Data on healthcare system delivery characteristics will
be collected via a survey conducted at the beginning of
the study and at the end of the study (to assess change).
The Facility Audit of Service Quality (FASQ) will be
Table 1 Outcomes and definitions
Outcomes Definition
Primary
Loss-to-follow-up Proportion of participants for whom the
whereabouts is unknown at: delivery,
6 weeks, 12 and 24 months postpartum
Virological suppression Proportion of participants with undetectable
viral loat at: delivery, 12 and 24 months
postpartum.
Secondary
Timely infant HIV
diagnosis
Proportion of HIV-exposed infant with an
appropriate HIV test result at 6 weeks,
12 and 24 months postpartum.
Timely ART initiation Proportion of HIV-infected participants
(mother and infant) initiated on ART
within 2 weeks of diagnosis
Retention in care Proportion of participants who are known
to be receiving HIV care 6 weeks, 12 and
24 months postpartum.
Non-adherence to
scheduled visits
Proportion of participants whose whereabouts
is unknown or who are in care but have
missed at least one scheduled visit over the
evaluation period at: delivery, 6 weeks, 12 and
24 months postpartum.
Virological suppression Proportion of participants with undetectable
viral load at: delivery, 12 and 24 months
postpartum.
MTCT rates Proportion of infants born to participating
women who tested positive for HIV at
6 weeks, 12 and 24 months postpartum.
Survival Proportion of participants known to be alive
at 6 weeks, 12 and 24 months postpartum.
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adapted to assess the key organizational characteristics of
HIV care (including lifelong ART) delivery in participating
MCH clinics. FASQ is a relatively low cost approach de-
veloped, by MEASURE Evaluation, for district level moni-
toring or service availability and quality [37]. It provides
information on the type of services; status and functional-
ity of infrastructure, equipment and quality of care. The
key areas covered include: 1) the range of services offered
(HIV testing and counseling, lifelong ART, laboratory),
staffing and staff qualifications, operating hours, commu-
nity linkages, selected administrative and quality control
procedures; 2) Facility infrastructure (privacy/capacity, la-
boratory, delivery, well-child clinics); 3) Readiness to pro-
vide quality care in six areas: family planning; STI
management; antenatal care; maternal/delivery care and
post abortion care; child health/welfare; and HIV preven-
tion, treatment, and care; and the digital maps of facilities
and services available.
Data on individual-level patient characteristics in-
cluding: socio-demographic and economic characteris-
tics, beliefs about the health services (cost, quality),
cognitive factors (knowledge about HIV and ART, per-
ceived susceptibility and perceived benefit of early ART,
perceived self-efficacy for adherence, perceived need for
ART and other HIV services), psychological factors (e.g.
depression, fear of stigma), social factors (social support
– friends, family, male partner involvement in MCH
care, intimate partner violence), and accessibility to the
clinics (distance, transportation, waiting time) will also
be collected through face to face interviews at enroll-
ment (within 1 month of ANC registration), after deliv-
ery (2–3 days in postpartum ward), at 6 weeks (6 weeks
post-partum visit), at 24 weeks (end of exclusive breast-
feeding period), and every 6 months thereafter through
the end of all breastfeeding exposure at 24 months.
Each completed questionnaire will be verified by a study
supervisor for completeness and consistency immediately
after the interview. Questionnaires with missing or incon-
stant responses will be returned to the interviewer for cor-
rection before data entry. The distribution of each variable
in the database will be generated on regular basis to also
check for completeness and consistency.
Statistical analyses
The frequencies of outcomes will be compared between
the intervention and control groups using adjusted
Pearson’s Chi-square [33]. All analyses will be intent-
to-treat, meaning that women will be kept in their ran-
domized group independently of whether they actually
received all their care in the group. The intervention
and control groups will be compared for baseline prognos-
tic factors and any imbalances that persist after
randomization will be adjusted for using logistic regression.
Within district- and clinic-level clustering will be accounted
for using the generalized estimating equation.
Ethical consideration
the study is approved by The Ohio State University insti-
tutional review board (Study ID: 2015H0440) and the
Kinshasa School of Public Health Ethical committee. All
participants will provide their signed informed consent.
Parental permission will be obtained before enrollment
of HIV-exposed infants. The protocol was retrospectively
registered to ClinicalTrials.gov on February 7, 2017,
2 months after the beginning of enrollment but before
randomization. : NCT03048669.
Discussion
The proposed study has multiple strengths. 1) The
comprehensive approach of the intervention in its abil-
ity to affect all three pillars of a health system delivery
performance: healthcare delivery systems, providers,
and beneficiaries (patients). Although there are a multi-
tude of trials evaluating different strategies to improve
retention in care and untimely the long-term outcomes
of HIV care in MCH clinics, virtually all of them
focused on the single patient components. 2) The
rigorous pragmatic design. Contrary to the only other
randomized trial currently evaluating CQI in Nigeria
[38], for which clinics were only eligible if they met a
minimum set of organizational criteria such as capacity to
provide ART until 12–18 months postpartum, provision
of postpartum care follow-up for HIV+ women, or avail-
ability of, at least, 2 trained community health extension
workers to be eligible, the only requirement to be part of
this study is to be one of the top three PMTCT providers
in the health districts. 3) The Potential for high impact: if
the CQI interventions are proven to be effective in im-
proving long-term outcomes of lifelong ART in MCH
clinics, it will provide the DRC government and PEP-
FAR with a scalable strategy to strengthen the quality
of HIV continuum of care and help the country and
PEPFAR move towards their aspiration of an AIDS-free
generation.
A source of concern for the proposed study is the
potential for crossover. This is an open label implemen-
tation science study that is being conducted in collabor-
ation of the Ministry of Health through the National
and Provincial AIDS Control Program, the main orga-
nizations that run most of the health care facilities in
Kinshasa (BDOM, Armée du Salut), as well as their
PMTCT implementing partners. Although we have
their support for the study, if through the study they
have the impression that one intervention developed
within the CQI could be of particular help in clinics
randomized to the control condition, it is possible they
may intentionally or inadvertently carry that intervention
Yotebieng et al. BMC Health Services Research  (2017) 17:306 Page 5 of 7
in other clinics they are responsible for. If this were to
happen, we have planned for robust data collection in the
pre-randomization phase on the outcomes to allow for a
pre- and post-intervention comparison of outcomes.
Conclusion
If the CQI interventions as designed in this study are
proven to be effective in improving long-term outcomes
of lifelong ART in MCH clinics, they will provide the
DRC government and PEPFAR with a scalable strategy to
strengthen the quality of the HIV continuum of care and
help the country and PEPFAR move towards their aspir-
ation of an AIDS-free generation. Because of the extreme
scarcity of resources in DRC settings, successful use of
CQI at scale to improve long-term outcomes of therapy in
women who start lifelong ART during pregnancy and
breastfeeding in this setting will entail that the interven-
tion can be used in virtually all settings.
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